← Back to Search

Chemotherapy

Ociperlimab for Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By You Lu
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months from first patient in date
Awards & highlights

Study Summary

This trial is testing a new combination of immunotherapy drugs to treat LS-SCLC patients. The drugs are ociperlimab, tislelizumab, and cCRT. This is a phase 2 trial, which means that it is testing whether the combination of these drugs is effective and has a tolerable safety profile.

Eligible Conditions
  • Small Cell Lung Cancer, Limited Stage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months from first patient in date
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months from first patient in date for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression free survival (PFS)
Secondary outcome measures
Complete Response (CR) rate as assessed by investigator per RECIST v1.1
Distant metastasis-free survival (DMFS)
Duration of response (DOR)
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm C: Concurrent Chemoradiotherapy (cCRT)Experimental Treatment1 Intervention
cCRT for 4 cycles
Group II: Arm B: TislelizumabExperimental Treatment2 Interventions
Tislelizumab + cCRT for 4 cycles followed by tislelizumab alone
Group III: Arm A: Ociperlimab + TislelizumabExperimental Treatment3 Interventions
Ociperlimab + tislelizumab + cCRT for 4 cycles followed by ociperlimab + tislelizumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ociperlimab
2021
Completed Phase 2
~400
Tislelizumab
2018
Completed Phase 3
~4270
Concurrent Chemoradiotherapy
2021
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

BeiGeneLead Sponsor
173 Previous Clinical Trials
27,880 Total Patients Enrolled
Study DirectorStudy DirectorBeiGene
1,202 Previous Clinical Trials
489,506 Total Patients Enrolled
You LuPrincipal InvestigatorWest China Hospital
2 Previous Clinical Trials
66 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor represent a pioneering effort?

"Since its initial trial in 2017, sponsored by BeiGene, Ociperlimab has been under intense scrutiny. The first phase 3 study involved 805 patients and resulted in the drug's approval. Today, there are 105 active trials for this medication taking place on 426 cities across 45 nations."

Answered by AI

What additional research projects have been conducted with regards to Ociperlimab?

"Ociperlimab was initially tested in 2017 at Uniwersyteckie Centrum Kliniczne. Up until now, 11 completed studies have been conducted and 105 active trials are underway with a great deal of them taking place around Wichita, Kansas."

Answered by AI

Are there any US sites currently conducting this investigation?

"This medical trial is accepting participants at 14 different sites, two of which being Wichita, Knoxville and Garden City. To minimise travel expenses associated with the study, it is recommended to enroll in a site that is closest by."

Answered by AI

Is this research project open for participant enrollment?

"It appears the clinicaltrial.gov records show that this study is not currently accepting new candidates; it was initially posted on July 15th 2021 and edited lastly April 25th 2022. Nonetheless, there are 1,677 other trials actively enrolling individuals right now."

Answered by AI

How many participants are involved in this research?

"Unfortunately, at this juncture in time, the listed clinical trial is not currently recruiting. The first posting was on July 15th 2021 and it had its most recent update on April 25th 2022. If you are searching for other studies to participate in, there are presently 1 572 trials that seek patients with small cell lung carcinoma and 105 trials actively looking for participants who would like to take ocriplimab."

Answered by AI

Has the regulatory body sanctioned Ociperlimab?

"There is clinical evidence backing the safety of Ociperlimab, which has earned it a score of 2 on our scale. However, Phase 2 does not entail any data that test its efficacy."

Answered by AI
~34 spots leftby Mar 2025